{"id":"imiquimod-5-cream","safety":{"commonSideEffects":[{"rate":"50-90","effect":"Local skin irritation (erythema, erosion, flaking)"},{"rate":"20-40","effect":"Pruritus"},{"rate":"20-40","effect":"Burning sensation"},{"rate":"30-60","effect":"Scabbing/crusting"},{"rate":"5-10","effect":"Flu-like symptoms (systemic)"},{"rate":"5-15","effect":"Lymphadenopathy"}]},"_chembl":{"chemblId":"CHEMBL1282","moleculeType":"Small molecule","molecularWeight":"240.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imiquimod binds to TLR7 on immune cells, triggering production of interferon-alpha and other cytokines that enhance local immune activation. This stimulates both innate and adaptive immune responses against abnormal skin cells, leading to clearance of lesions. The mechanism is particularly effective for treating viral-induced and pre-malignant skin conditions.","oneSentence":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:06.993Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"},{"name":"Basal cell carcinoma (superficial and nodular)"},{"name":"Genital warts (external)"},{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"}]},"trialDetails":[{"nctId":"NCT07210775","phase":"PHASE1, PHASE2","title":"Topical Imiquimod Treatment of Oral Dysplasia","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2025-10-01","conditions":"Oral Dysplasia, Leukoplakia Oral, Leukoplakia","enrollment":20},{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT07251413","phase":"PHASE1, PHASE2","title":"Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2025-10-22","conditions":"Cutaneous Basal Cell Carcinoma","enrollment":18},{"nctId":"NCT04808245","phase":"PHASE1","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-02-15","conditions":"Newly Diagnosed H3-mutated Glioma","enrollment":15},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT03370406","phase":"PHASE1","title":"Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC","status":"RECRUITING","sponsor":"Melissa Pugliano-Mauro","startDate":"2018-08-03","conditions":"Carcinoma, Squamous Cell","enrollment":30},{"nctId":"NCT06973473","phase":"","title":"Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts:Randomized Comparative Trial.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-07-01","conditions":"Warts","enrollment":60},{"nctId":"NCT06840470","phase":"PHASE4","title":"Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-03-11","conditions":"Sebaceous Hyperplasia","enrollment":40},{"nctId":"NCT01926496","phase":"PHASE4","title":"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09-11","conditions":"Actinic Keratosis (AK)","enrollment":485},{"nctId":"NCT02889159","phase":"PHASE1","title":"Immunologic Profile of Chronically Photodamaged Skin","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2016-06-06","conditions":"Photoaged Skin, Normal Skin","enrollment":40},{"nctId":"NCT02078648","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2014-05","conditions":"Adult Brain Glioblastoma, Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT04883645","phase":"EARLY_PHASE1","title":"Neoadjuvant Imiquimod Immunotherapy for Oral Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2022-04-28","conditions":"Oral Squamous Cell Carcinoma","enrollment":16},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT02394132","phase":"PHASE3","title":"Radiotherapy or Imiquimod in Complex Lentigo Maligna","status":"COMPLETED","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2015-08-31","conditions":"Lentigo Maligna","enrollment":126},{"nctId":"NCT06411106","phase":"NA","title":"Deep Phenotyping of Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2024-06","conditions":"Cutaneous Lupus Erythematosus","enrollment":40},{"nctId":"NCT05838599","phase":"EARLY_PHASE1","title":"Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-07-24","conditions":"Mycosis Fungoides","enrollment":25},{"nctId":"NCT03180684","phase":"PHASE2","title":"Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2017-08-31","conditions":"Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN)","enrollment":33},{"nctId":"NCT00314756","phase":"PHASE4","title":"Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2005-03","conditions":"Basal Cell Carcinoma","enrollment":15},{"nctId":"NCT05740969","phase":"PHASE2","title":"Gene and Protein Expression Profiles After Treatment of Actinic Keratoses","status":"UNKNOWN","sponsor":"Ismail Gögenur","startDate":"2023-02-01","conditions":"Actinic Keratoses","enrollment":48},{"nctId":"NCT05468606","phase":"EARLY_PHASE1","title":"Coadministration of GA2 Sporozoites With Adjuvants","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-02-03","conditions":"Malaria,Falciparum","enrollment":45},{"nctId":"NCT01720407","phase":"PHASE3","title":"Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-12","conditions":"Lentigo Maligna Melanoma (Head or Neck)","enrollment":259},{"nctId":"NCT00585247","phase":"NA","title":"Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2006-11","conditions":"Port Wine Stain","enrollment":27},{"nctId":"NCT00142454","phase":"PHASE1","title":"NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2005-08-24","conditions":"Malignant Melanoma","enrollment":9},{"nctId":"NCT01808820","phase":"PHASE1","title":"Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma","status":"COMPLETED","sponsor":"Macarena De La Fuente, MD","startDate":"2013-08-21","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":20},{"nctId":"NCT04083157","phase":"PHASE2, PHASE3","title":"Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-08-12","conditions":"Inflammatory Bowel Diseases, Hepatitis B","enrollment":104},{"nctId":"NCT05314127","phase":"PHASE2","title":"Efficacy of Tazarotene in Treatment of Verruca Plana","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-04-15","conditions":"Warts Flat","enrollment":80},{"nctId":"NCT05315024","phase":"NA","title":"Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-30","conditions":"Influenza","enrollment":72},{"nctId":"NCT00189280","phase":"PHASE3","title":"Aldara for the Treatment of Large and/or Multiple sBCC","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2003-05","conditions":"Carcinoma, Basal Cell","enrollment":111},{"nctId":"NCT01453179","phase":"PHASE4","title":"Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2011-10","conditions":"Actinic Keratosis","enrollment":221},{"nctId":"NCT00189267","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2002-11","conditions":"Actinic Keratosis","enrollment":45},{"nctId":"NCT00189293","phase":"PHASE4","title":"Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2005-06","conditions":"Genital Warts","enrollment":128},{"nctId":"NCT00761371","phase":"PHASE4","title":"Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2002-08","conditions":"Warts","enrollment":52},{"nctId":"NCT00294320","phase":"PHASE3","title":"Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2006-02","conditions":"Actinic Keratosis","enrollment":12},{"nctId":"NCT00189241","phase":"PHASE3","title":"A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2001-02","conditions":"Basal Cell Carcinoma","enrollment":160},{"nctId":"NCT00777127","phase":"PHASE4","title":"Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2008-12","conditions":"Actinic Keratosis","enrollment":258},{"nctId":"NCT00189254","phase":"","title":"A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2005-04","conditions":"Actinic Keratoses","enrollment":72},{"nctId":"NCT01421017","phase":"PHASE1, PHASE2","title":"Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2011-08-19","conditions":"Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":31},{"nctId":"NCT04279535","phase":"EARLY_PHASE1","title":"Topical Vitamin C for Treatment of Basal Cell Cancer","status":"COMPLETED","sponsor":"Center for Biomedical Research, Inc.","startDate":"2018-03-01","conditions":"Basal Cell Carcinoma","enrollment":25},{"nctId":"NCT02242929","phase":"PHASE3","title":"Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2016-01","conditions":"Nodular Basal Cell Carcinoma","enrollment":145},{"nctId":"NCT03982004","phase":"PHASE1","title":"Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer","enrollment":1},{"nctId":"NCT04859361","phase":"NA","title":"Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ","status":"UNKNOWN","sponsor":"University Medical Centre Maribor","startDate":"2018-11-20","conditions":"Intraepithelial Neoplasia, Cervical","enrollment":104},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT03233412","phase":"PHASE2","title":"Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions","status":"COMPLETED","sponsor":"Barretos Cancer Hospital","startDate":"2018-01-01","conditions":"High Grade Intraepithelial Neoplasia, Cervix Cancer","enrollment":90},{"nctId":"NCT02482428","phase":"PHASE2","title":"Efficacy and Tolerability of Topical LFX453 for External Genital Warts","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-12","conditions":"External Genital Warts","enrollment":88},{"nctId":"NCT03760250","phase":"PHASE2","title":"Imiquimod for Preventing Keloid Recurrence","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2019-02-05","conditions":"Keloid","enrollment":6},{"nctId":"NCT03289260","phase":"PHASE3","title":"Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-11-15","conditions":"Anogenital Human Papillomavirus Infection, Condyloma Anal","enrollment":200},{"nctId":"NCT00948428","phase":"PHASE3","title":"Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2008-05","conditions":"Actinic Keratoses","enrollment":462},{"nctId":"NCT02293707","phase":"PHASE2","title":"A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Laboratoires Leurquin Mediolanum","startDate":"2014-11","conditions":"Prostate Cancer","enrollment":99},{"nctId":"NCT04072900","phase":"PHASE1","title":"A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-04-21","conditions":"Melanoma (Skin)","enrollment":30},{"nctId":"NCT02224599","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies","status":"TERMINATED","sponsor":"Kiromic BioPharma Inc.","startDate":"2017-07-28","conditions":"Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer","enrollment":3},{"nctId":"NCT01400672","phase":"PHASE1","title":"Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-07-17","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":8},{"nctId":"NCT03472976","phase":"PHASE1","title":"H5N1 With or Without Topical Aldara in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-06-13","conditions":"Avian Influenza, Influenza Immunisation","enrollment":50},{"nctId":"NCT03901690","phase":"PHASE3","title":"Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study","status":"UNKNOWN","sponsor":"Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri","startDate":"2019-08-27","conditions":"Genital Wart Virus Infection","enrollment":102},{"nctId":"NCT02385188","phase":"PHASE3","title":"Topical 5% Imiquimod Cream for Vulvar Paget's Disease","status":"COMPLETED","sponsor":"University Medical Center Nijmegen","startDate":"2015-05","conditions":"Paget Disease, Extramammary","enrollment":25},{"nctId":"NCT02621112","phase":"PHASE2, PHASE3","title":"HBV Vaccine in Renal Failure Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-01","conditions":"Renal Failure","enrollment":94},{"nctId":"NCT01088737","phase":"PHASE2, PHASE3","title":"Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna","status":"UNKNOWN","sponsor":"Medical University of Graz","startDate":"2011-01","conditions":"Lentigo Maligna","enrollment":60},{"nctId":"NCT02234921","phase":"PHASE1","title":"Pilot Study of DRibble Vaccine for Prostate Cancer Patients","status":"COMPLETED","sponsor":"UbiVac","startDate":"2014-10-24","conditions":"Adenocarcinoma of the Prostate","enrollment":3},{"nctId":"NCT02329171","phase":"PHASE3","title":"Imiquimod Treatment of CIN Lesions","status":"TERMINATED","sponsor":"Maastricht University Medical Center","startDate":"2014-12","conditions":"Cervical Intraepithelial Neoplasia","enrollment":9},{"nctId":"NCT00638651","phase":"PHASE1","title":"Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal","status":"COMPLETED","sponsor":"University of Miami","startDate":"2008-02","conditions":"Healthy","enrollment":3},{"nctId":"NCT02669459","phase":"PHASE3","title":"Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2016-05","conditions":"Cervical Intraepithelial Neoplasia","enrollment":433},{"nctId":"NCT01171469","phase":"PHASE1","title":"Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2010-09","conditions":"Brain Tumor, Glioblastoma, Medulloblastoma","enrollment":8},{"nctId":"NCT02960815","phase":"PHASE2","title":"Imiquimod and Influenza Vaccine for Immunocompromised Patients","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2016-11","conditions":"Influenza Vaccine","enrollment":70},{"nctId":"NCT01538901","phase":"PHASE4","title":"Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2012-09","conditions":"Actinic Keratoses","enrollment":10},{"nctId":"NCT01909752","phase":"PHASE2","title":"Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"UbiVac","startDate":"2013-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":12},{"nctId":"NCT00849992","phase":"PHASE4","title":"Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2009-03","conditions":"Actinic Cheilitis","enrollment":53},{"nctId":"NCT01059110","phase":"PHASE4","title":"Comparison of Five Treatments in Patients With Plantar Warts","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-02","conditions":"Plantar Warts","enrollment":358},{"nctId":"NCT00865644","phase":"PHASE1","title":"Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-03","conditions":"Neurofibromatosis Type 1, Cutaneous Neurofibromas","enrollment":11},{"nctId":"NCT01264731","phase":"PHASE1","title":"Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2011-01","conditions":"Melanoma","enrollment":4},{"nctId":"NCT02689726","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL","status":"TERMINATED","sponsor":"Genticel","startDate":"2015-08","conditions":"HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL","enrollment":13},{"nctId":"NCT01957878","phase":"PHASE2","title":"Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL","status":"COMPLETED","sponsor":"Genticel","startDate":"2013-12","conditions":"Genital Infection Viral, HUMAN PAPILLOMA VIRUS","enrollment":239},{"nctId":"NCT00774787","phase":"PHASE4","title":"Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses","status":"COMPLETED","sponsor":"Rigel Dermatology","startDate":"2008-10","conditions":"Actinic Keratoses","enrollment":27},{"nctId":"NCT00470392","phase":"NA","title":"Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2007-05","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT00899574","phase":"PHASE2","title":"Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-05","conditions":"Breast Cancer, Breast Neoplasms","enrollment":10},{"nctId":"NCT00230373","phase":"PHASE3","title":"Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2005-11","conditions":"Morphea","enrollment":""},{"nctId":"NCT02103023","phase":"PHASE3","title":"Intradermal Influenza Vaccine in the Young","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2014-03","conditions":"Influenza Viral Infections","enrollment":160},{"nctId":"NCT00176943","phase":"PHASE4","title":"Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%","status":"COMPLETED","sponsor":"Hordinsky, Maria K., MD","startDate":"2000-10","conditions":"Alopecia Areata","enrollment":20},{"nctId":"NCT00828568","phase":"PHASE1","title":"Bioequivalence Study of Two Imiquimod Cream 5%","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2008-06","conditions":"Actinic Keratosis","enrollment":425},{"nctId":"NCT00066872","phase":"PHASE3","title":"Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer","status":"COMPLETED","sponsor":"Queen's Medical Center","startDate":"2002-10","conditions":"Non-melanomatous Skin Cancer","enrollment":500},{"nctId":"NCT01935310","phase":"NA","title":"Photoaging Treatment With Imiquimod","status":"COMPLETED","sponsor":"CES University","startDate":"2010-07","conditions":"Photoaging","enrollment":17},{"nctId":"NCT00147771","phase":"PHASE3","title":"Imiquimod in Children With Plaque Morphea","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2005-09","conditions":"Scleroderma, Localized","enrollment":10},{"nctId":"NCT00707174","phase":"NA","title":"Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-03","conditions":"Cancer, Lentigo Maligna","enrollment":90},{"nctId":"NCT00079300","phase":"PHASE1","title":"Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer","status":"COMPLETED","sponsor":"National Naval Medical Center","startDate":"2004-01","conditions":"Non-melanomatous Skin Cancer","enrollment":""},{"nctId":"NCT00273910","phase":"PHASE2","title":"Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-01","conditions":"High-Risk Melanoma","enrollment":104},{"nctId":"NCT01161888","phase":"PHASE4","title":"Effect of Topical Imiquimod on Lentigo Maligna","status":"COMPLETED","sponsor":"Jerry Marsden","startDate":"2010-06","conditions":"Lentigo Maligna","enrollment":30},{"nctId":"NCT00803907","phase":"PHASE4","title":"Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2008-12","conditions":"Carcinoma, Basal Cell","enrollment":20},{"nctId":"NCT00204555","phase":"PHASE4","title":"Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2002-01","conditions":"Carcinoma, Basal Cell","enrollment":100},{"nctId":"NCT01380314","phase":"PHASE2","title":"Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Foundation Fader","startDate":"2008-03","conditions":"Cutaneous Leishmaniasis","enrollment":60},{"nctId":"NCT00189306","phase":"PHASE3","title":"Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2001-03","conditions":"Superficial Basal Cell Carcinoma","enrollment":169},{"nctId":"NCT00335179","phase":"PHASE2","title":"Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2003-01","conditions":"Actinic Keratosis","enrollment":17},{"nctId":"NCT00116649","phase":"PHASE4","title":"Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2005-06","conditions":"Keratosis","enrollment":551},{"nctId":"NCT00129519","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2004-01","conditions":"Basal Cell Carcinoma","enrollment":63},{"nctId":"NCT00859105","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis","status":"COMPLETED","sponsor":"Apotex Inc.","startDate":"2008-02","conditions":"Actinic Keratosis","enrollment":497},{"nctId":"NCT00110682","phase":"PHASE4","title":"Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses","status":"COMPLETED","sponsor":"Derm Research @ 888 Inc.","startDate":"2005-04","conditions":"Keratosis, Actinic Keratosis","enrollment":60},{"nctId":"NCT00601016","phase":"PHASE2","title":"A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy","status":"COMPLETED","sponsor":"St. Justine's Hospital","startDate":"2005-03","conditions":"Hemangioma, Capillary","enrollment":18},{"nctId":"NCT00115154","phase":"PHASE4","title":"Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2005-05","conditions":"Keratosis","enrollment":270},{"nctId":"NCT00114023","phase":"","title":"1-Year Follow up to the 1473-IMIQ Study","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2005-01","conditions":"Keratosis","enrollment":84},{"nctId":"NCT00177021","phase":"PHASE4","title":"Aldara for the Treatment of Extensive Alopecia Areata","status":"COMPLETED","sponsor":"Hordinsky, Maria K., MD","startDate":"2000-10","conditions":"Alopecia Areata","enrollment":20},{"nctId":"NCT00175643","phase":"PHASE3","title":"Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-02","conditions":"Actinic Keratoses","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":557,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aldera","Imiquimod 5% cream = Aldara","Item ID = GH-6203-0328-5, CUP-051119552409","DIN number = 02239505","Lot number -= GFK026A"],"phase":"marketed","status":"active","brandName":"Imiquimod 5% Cream","genericName":"Imiquimod 5% Cream","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions. Used for Actinic keratosis, Basal cell carcinoma (superficial and nodular), Genital warts (external).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}